Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, Sweden - April 26 2024 - OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager.
As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is pleased to confirm the appointment of Anna Asplind as Phase 3 Program Manager in support of OncoZenge's role as sponsor of the project.
Anna Asplind has more than 20 years of experience from leading and managing large cross-functional, national and international, project teams within the pharmaceutical industry across Phase I to Phase IV. She started her career as a registered nurse, followed by more than 10 years in various clinical research roles, across several therapeutic areas, at AstraZeneca, with more than 10 years leading projects at several Clinical Research Organizations after that.
OncoZenge has entered a collaboration with PharmaRelations to establish the foundation of its sponsor oversight function. Anna now joins Åsa Nilsson (Clinical Research Manager) and Mihai-Andrei Florescu (Quality Assurance/GxP) in her role as Phase 3 Program Manager.
"We are thrilled to welcome Anna to OncoZenge", says Stian Kildal, CEO of OncoZenge. "Anna brings with her experience and seniority to ensure OncoZenge can work effectively with a partner to finalize the scope, plans and preparations for regulatory approval for initiating our pivotal phase 3-project. With this appointment we have identified the core team for our sponsor oversight, and thus secured capabilities and readiness for kicking off the program, pending our decision on strategic partner", Stian concludes.
BupiZenge™ - Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
Certified Adviser
OncoZenge's Certified Adviser is Carnegie Investment Bank AB (publ).
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial.
OncoZenge has its headquarters in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.